Crisaborole
- CAS No.
- 906673-24-3
- Chemical Name:
- Crisaborole
- Synonyms
- 4-[(1,3-Dihydro-1-hydroxy-2,1-benzoxaborol-5-yl)oxy]benzonitrile AN 2728;AN 2728;CS-1895;Cleboro;Creborol;Crisaborole;PF-06930164;AN2728/AN-2728;AN-2728, >=98%;Crisaborole EP
- CBNumber:
- CB42518350
- Molecular Formula:
- C14H10BNO3
- Molecular Weight:
- 251.05
- MOL File:
- 906673-24-3.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/9/5 22:20:32
| Melting point | >130°C (softened) |
|---|---|
| Boiling point | 425.9±55.0 °C(Predicted) |
| Density | 1.33±0.1 g/cm3(Predicted) |
| storage temp. | room temp |
| solubility | DMSO (Slightly), Methanol (Slightly) |
| pka | 7.00±0.20(Predicted) |
| form | powder |
| color | white to beige |
| Stability | Hygroscopic |
| InChI | InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2 |
| InChIKey | USZAGAREISWJDP-UHFFFAOYSA-N |
| SMILES | C(#N)C1=CC=C(OC2=CC=C3B(O)OCC3=C2)C=C1 |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS06 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H301+H331-H315-H319-H335 | |||||||||
| Precautionary statements | P261-P301+P310-P305+P351+P338-P311 | |||||||||
| NFPA 704 |
|
Crisaborole price More Price(2)
Crisaborole Chemical Properties,Uses,Production
Description
Crisaborole is a phosphodiesterase- 4 (PDE4) inhibitor that was approved by FDA on December 14, 2016 as Eucrisa, a topical treatment of for mild to moderate atopic dermatitis (AD) in patients aged two years and older. The drug, which was developed by Anacor Pharmaceuticals and later acquired and marketed by Pfizer, is delivered as a 2% ointment, which is applied topically. Its structure contains a boron atom, which facilitates skin penetration and binding to the bimetal center of the phosphodiesterase 4 enzyme. The unique employment of boron within the chemical structure of the drug is designed to enable selective engagement of PDE4 (an enzyme involved in the conversion of cAMP into AMP, which signals for downstream inflammatory events), effective penetration of the drug through human skin, and rapid clearance to limit systemic circulation.
Uses
A series of phenoxy benzoxaboroles were synthesized and screened for their inhibitory activity against PDE4 and cytokine release. 5-(4-Cyanophenoxy)-2,3-dihydro-1-hydroxy-2,1-benzoxaborole (AN2728) showed potent activity both in vitro and in vivo. AN2728 is being studied as an anti-inflammatory agent.
Definition
ChEBI: Crisaborole is a member of the class of benzoxaboroles that is 5-hydroxy-1,3-dihydro-2,1-benzoxaborole in which the phenolic hydrogen has been replaced by a 4-cyanophenyl group. A phosphodiesterase 4 inhibitor that is used for treatment of mild to moderate atopic dermatitis in children and adults. It has a role as a phosphodiesterase IV inhibitor, an antipsoriatic and a non-steroidal anti-inflammatory drug. It is a benzoxaborole, an aromatic ether and a nitrile. ?
Side effects
EUCRISA may cause side effects.
Allergic reactions. EUCRISA may cause allergic reactions at or near the application site. These can be serious and may include hives, itching, swelling, and redness.
www.eucrisa.com
Mode of action
Crisaborole is a Phosphodiesterase 4 Inhibitor. The mechanism of action of crisaborole is as a Phosphodiesterase 4 Inhibitor.
Crisaborole Preparation Products And Raw materials
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Halcyon Labs Pvt. Ltd | +919833750169 | Mumbai, India | 17 | 58 | Inquiry |
| Viruj Pharmaceuticals Pvt Ltd | +91-9441591589 +91-9441591589 | Hyderabad, India | 33 | 58 | Inquiry |
| Metrochem API Private Limited | +91-4069069999 +91-4069069999 | Telangana, India | 78 | 58 | Inquiry |
| Honour Lab Limited | +919845977466 | Telangana, India | 164 | 58 | Inquiry |
| Virupaksha Organics Pvt Ltd | +91-9440049755 +91-9848648601 | Telangana, India | 40 | 58 | Inquiry |
| Biophore India Pharmaceuticals Pvt Ltd | +91-9100031592 +91-9030907714 | Telangana, India | 134 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| CHEMSWORTH | +91-261-2397244 | New Delhi, India | 6707 | 30 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| Pharmaffiliates Analytics and Synthetics P. Ltd | +91-172-5066494 | Haryana, India | 6773 | 58 | Inquiry |
Related articles
- Crisaborole ointment: Indications, Safety and Efficacy
- Crisaborole has broad-spectrum anti-inflammatory activity by mainly targeting phosphodiesterase 4 (PDE4) enzyme that is a key ....
- Aug 12，2024
- Crisaborole: A Boron-Containing Molecule with Therapeutic Efficacy in Treating Atopic Dermatitis
- Crisaborole inhibits PDE4, increasing cAMP levels, with well-tolerated topically and minimally absorbed systemically. Effectiv....
- Feb 6，2024
- Therapeutic potential and mechanism of action of Crisaborole
- Crisaborole is a non-steroidal topical medication for the treatment of mild-moderate atopic dermatitis.
- Nov 9，2023